146
Analyzed patients
Clinical research
Published evidence, clearly defined.
The STEFANO study evaluated OnLife®—the formulation available in the United States as Novilora™—in people with established chemotherapy-induced peripheral neuropathy.
21
Oncology centers
3 months
Treatment / evaluation
Prospective
Single-arm observational
Breast cancer
The strongest study signal was observed among patients with paclitaxel-induced neuropathy.
Colon cancer
The study separately evaluated outcomes among patients with oxaliplatin-induced neuropathy.
An observational signal—not proof of causation
STEFANO was prospective and multicenter, but it was not randomized or placebo-controlled. The findings cannot establish how much observed improvement was attributable to OnLife® versus treatment-independent recovery after chemotherapy.
Primary study source
Zaiss M, Uhlig J, Zahn M-O, et al. Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO. Oncology Research and Treatment. 2021. DOI: 10.1159/000519000.